Literature DB >> 16463039

Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells.

Cheryl L-L Chiang1, Jonathan A Ledermann, Ariel N Rad, David R Katz, Benjamin M Chain.   

Abstract

BACKGROUND: Ovarian cancer commonly relapses after remission and new strategies to target microscopic residual diseases are required. One approach is to activate tumor-specific cytotoxic T cells with dendritic cells loaded with tumor cells. In order to enhance their immunogenicity, ovarian tumor cells (SK-OV-3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl).
RESULTS: Treatment for 1 h with 60 microM HOCl was found to induce necrosis in all SK-OV-3 cells. Oxidized, but not live, SK-OV-3 was rapidly taken up by monocyte-derived dendritic cells, and induced partial dendritic cell maturation. Dendritic cells cultured from HLA-A2 healthy volunteers were loaded with oxidized SK-OV-3 (HLA-A2-) and co-cultured with autologous T cells. Responding T cells were tested for specificity after a further round of antigen stimulation. In ELISPOT assays, T cells produced interferon-gamma (IFN-gamma) in response to the immunizing cellular antigen, and also to peptides coding for MUC-1 and HER-2/neu HLA-A2 restricted epitopes, demonstrating efficient cross-presentation of cell-associated antigens. In contrast, no responses were seen after priming with heat-killed or HCl-killed SK-OV-3, indicating that HOCl oxidation and not cell death/necrosis per se enhanced the immunogenicity of SK-OV-3. Finally, T cells stimulated with oxidized SK-OV-3 showed no cross-reaction to oxidized melanoma cells, nor vice versa, demonstrating that the response was tumor-type specific.
CONCLUSIONS: Immunization with oxidized ovarian tumor cell lines may represent an improved therapeutic strategy to stimulate a polyclonal anti-tumor cellular immune response and hence extend remission in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463039     DOI: 10.1007/s00262-006-0127-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

Review 1.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

2.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 3.  Engineering opportunities in cancer immunotherapy.

Authors:  Laura Jeanbart; Melody A Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 4.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

5.  Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease.

Authors:  Nicola Hardwick; Jonathan A Ledermann; Egla Aitkens; Benny Chain
Journal:  Cancer Immunol Immunother       Date:  2012-04-05       Impact factor: 6.968

6.  Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Authors:  Cheryl Lai-Lai Chiang; Andrea R Hagemann; Rachel Leskowitz; Rosemarie Mick; Thomas Garrabrant; Brian J Czerniecki; Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

7.  Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Authors:  Cheryl L-L Chiang; Dawn A Maier; Lana E Kandalaft; Andrea L Brennan; Evripidis Lanitis; Qunrui Ye; Bruce L Levine; Brian J Czerniecki; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2011-11-14       Impact factor: 5.531

8.  A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Cheryl L Chiang; Janos Tanyi; Greg Motz; Klara Balint; Rosemarie Mick; George Coukos
Journal:  J Transl Med       Date:  2013-06-18       Impact factor: 5.531

9.  Biophysical insights into cancer transformation and treatment.

Authors:  Jiří Pokorný; Alberto Foletti; Jitka Kobilková; Anna Jandová; Jan Vrba; Jan Vrba; Martina Nedbalová; Aleš Čoček; Andrea Danani; Jack A Tuszyński
Journal:  ScientificWorldJournal       Date:  2013-06-11

10.  Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.

Authors:  Iart Luca Shytaj; Barbara Chirullo; Wendeline Wagner; Maria G Ferrari; Rossella Sgarbanti; Alessandro Della Corte; Celia LaBranche; Lucia Lopalco; Anna Teresa Palamara; David Montefiori; Mark G Lewis; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2013-07-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.